These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37936701)

  • 1. Amplifying mRNA vaccines: potential versatile magicians for oncotherapy.
    Hu C; Liu J; Cheng F; Bai Y; Mao Q; Xu M; Liang Z
    Front Immunol; 2023; 14():1261243. PubMed ID: 37936701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.
    Maruggi G; Ulmer JB; Rappuoli R; Yu D
    Curr Top Microbiol Immunol; 2022; 440():31-70. PubMed ID: 33861374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future.
    Perenkov AD; Sergeeva AD; Vedunova MV; Krysko DV
    Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37897003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances and applications of RNA vaccines in tumor treatment.
    Yang R; Cui J
    Mol Cancer; 2024 Oct; 23(1):226. PubMed ID: 39385255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
    Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
    J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 mRNA vaccines: Platforms and current developments.
    Szabó GT; Mahiny AJ; Vlatkovic I
    Mol Ther; 2022 May; 30(5):1850-1868. PubMed ID: 35189345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New Hopes in Vaccine Technology: mRNA Vaccines].
    Yılmaz E
    Mikrobiyol Bul; 2021 Apr; 55(2):265-284. PubMed ID: 33882657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-amplifying mRNA vaccines.
    Brito LA; Kommareddy S; Maione D; Uematsu Y; Giovani C; Berlanda Scorza F; Otten GR; Yu D; Mandl CW; Mason PW; Dormitzer PR; Ulmer JB; Geall AJ
    Adv Genet; 2015; 89():179-233. PubMed ID: 25620012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines as promising immuno-therapeutics: platforms and current progress.
    Liu J; Fu M; Wang M; Wan D; Wei Y; Wei X
    J Hematol Oncol; 2022 Mar; 15(1):28. PubMed ID: 35303904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Amplifying RNA Vaccine Candidates: Alternative Platforms for mRNA Vaccine Development.
    Schmidt C; Schnierle BS
    Pathogens; 2023 Jan; 12(1):. PubMed ID: 36678486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization.
    Pourseif MM; Masoudi-Sobhanzadeh Y; Azari E; Parvizpour S; Barar J; Ansari R; Omidi Y
    Drug Discov Today; 2022 Nov; 27(11):103341. PubMed ID: 35988718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA vaccine in cancer therapy: Current advance and future outlook.
    Li Y; Wang M; Peng X; Yang Y; Chen Q; Liu J; She Q; Tan J; Lou C; Liao Z; Li X
    Clin Transl Med; 2023 Aug; 13(8):e1384. PubMed ID: 37612832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA vaccines for cancer immunotherapy.
    Vishweshwaraiah YL; Dokholyan NV
    Front Immunol; 2022; 13():1029069. PubMed ID: 36591226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing mRNA technologies for therapies and vaccines: An African context.
    Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
    Front Immunol; 2022; 13():1018961. PubMed ID: 36353641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines.
    Démoulins T; Milona P; Englezou PC; Ebensen T; Schulze K; Suter R; Pichon C; Midoux P; Guzmán CA; Ruggli N; McCullough KC
    Nanomedicine; 2016 Apr; 12(3):711-722. PubMed ID: 26592962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.
    Maruggi G; Zhang C; Li J; Ulmer JB; Yu D
    Mol Ther; 2019 Apr; 27(4):757-772. PubMed ID: 30803823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies.
    Li H; Peng K; Yang K; Ma W; Qi S; Yu X; He J; Lin X; Yu G
    Theranostics; 2022; 12(14):6422-6436. PubMed ID: 36168634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.